News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Joins NHIA Future of Infusion Advisory Council
For Melinta, membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies. This work helps to enhance continuity of care as patients transition out of the hospital.
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
May 15, 2023 Press Release Parsippany, New Jersey and Ontario, Canada, May 15, 2023 – Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
March 22, 2023 Press Release – REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
January 24, 2023 Press Release FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive